Cancer research
Getting started guides
)
A guide to transcriptomics with Oxford Nanopore
This guide introduces cDNA and direct RNA Oxford Nanopore sequencing, for ultra-rich transcriptomic data without compromise.
)
A guide to targeted sequencing with Oxford Nanopore
This guide provides an introduction to performing targeted nanopore sequencing.
)
A guide to human genomics with Oxford Nanopore
This guide introduces how to sequence human genomes with Oxford Nanopore, from the construction of new, highly complete reference assemblies to the comprehensive identification of variants.
)
A guide to investigating methylation in the human genome
This guide provides an introduction to the direct sequencing of DNA methylation in human genomes.
)
A guide to single-cell transcriptomics with Oxford Nanopore
This guide introduces the single-cell RNA nanopore sequencing workflow, for ultra-rich data without compromise.
Most viewed
)
Multiomic nanopore sequencing: revolutionising human disease research
Find out how multiomic nanopore sequencing can accelerate your disease research using a single platform.
)
PromethION 24: sequencing to the power of 24
Multiply your insights with PromethION 24, the production-scale nanopore sequencer that puts you in control of up to 24 high-output flow cells. Discover more.
)
PromethION 2 Integrated: small box, big picture
Explore the PromethION 2 Integrated and bring high-output Oxford Nanopore sequencing to your lab. Run up to two independent flow cells with onboard compute for real-time insights. Discover more.
)
Accelerate your epigenetics research with Oxford Nanopore sequencing
In this flyer, find out how Oxford Nanopore sequencing uncovers the complete methylome and provides highly accurate and comprehensive base modification data for analysis.
)
Hereditary Cancer Panel: targeted sequencing via adaptive sampling
In this flyer, discover how to utilise the Oxford Nanopore Hereditary Cancer Panel to investigate 258 key genes associated with hereditary cancer risk.
Workflow overviews
)
Comprehensive characterisation of cancer predisposition genes using the Hereditary Cancer Panel
Discover the Hereditary Cancer Panel workflow and streamline your precision oncology research.
)
Sequencing full-length transcripts for isoform-level expression analysis
This end-to-end workflow provides a flexible method to sequence full-length transcripts for isoform-level expression analysis.
)
Characterising genomic and epigenomic variation between tumour-normal research samples using long nanopore sequencing reads
This end-to-end workflow overview provides a simple solution for detecting a wide range of tumour-specific variation in a single sequencing assay.
)
Obtaining full-length isoforms from single cells with Oxford Nanopore sequencing
This end-to-end workflow provides a simple solution for single-cell transcriptome analysis from 10x Genomics cDNA with library preparation in approximately three hours.
)
Comprehensive human genomic variant and methylation analysis with long Oxford Nanopore reads
This end-to-end workflow provides a scalable method to identify previously hidden and potentially pathogenic variants.
Featured resources
)
New approaches for human and clinical research
Explore the advantages of Oxford Nanopore sequencing to detect genomic and epigenomic variants in human and clinical research.
)
Accelerating cancer research through comprehensive genomic analysis
Unlock previously hidden variation with nanopore sequencing and characterise cancer at unprecedented resolution.
)
From speed to scale: how do I choose the right human whole-genome sequencing workflow for my experiment?
In this masterclass, find the right human whole-genome sequencing workflow to meet your experimental goals. We’ll cover whole-genome analysis in just 24 hours through to scaling sequencing for large cohort research. In this masterclass, discover: • How Oxford Nanopore sequencing is advancing human g
)
How do I analyse my Oxford Nanopore sequencing data without specialist training?
In this beginner-friendly masterclass, discover how to analyse your Oxford Nanopore sequencing data. Find out how basecalling works, the common file formats you’ll encounter, and how to use MinKNOW to set up and monitor your sequencing run. Then, discover how to analyse your data with EPI2ME — no pr
)
Which library prep workflow is right for my experiment?
Whether you’re sequencing DNA, RNA, or cDNA, a single sample or many in multiplex, there’s an Oxford Nanopore library prep kit for you. In this masterclass, discover how to choose the right one for your workflow. In this masterclass, discover: • The range of Oxford Nanopore library prep solutions av
Protocols
Analysis workflows
wf-somatic-variation
This workflow calls variants from the alignment files of a paired tumor/normal sample.
Latest research
)
Identification of a novel intergenic EPCAM-MSH2 deletion causing EPCAM-associated Lynch syndrome by long-read nanopore sequencing
Publication: Identification of a novel intergenic EPCAM-MSH2 deletion causing EPCAM-associated Lynch syndrome by long-read nanopore sequencing
)
Addressing the global diagnostics gap for childhood leukaemias: a global, multisite type 2 hybrid validation study of nanopore-based Adaptive Sampling whole-genome sequencing
Publication: Addressing the global diagnostics gap for childhood leukaemias: a global, multisite type 2 hybrid validation study of nanopore-based Adaptive Sampling whole-genome sequencing
)
Digital panels enable targeted enrichment of haematological cancer-associated genomic regions during sequencing
Discover how nanopore sequencing with Adaptive Sampling can target cancer-associated genes from blood-derived and bone marrow-derived DNA.
)
Oxford Nanopore Adaptive Sampling for tumour-only SNV, SV, and CNV profiling in one assay
Discover how nanopore sequencing with Adaptive Sampling reveals tumour-only SNVs, SVs, and CNVs in one assay.
)
Accelerating precision oncology: Real-time genomic and epigenomic profiling with Oxford Nanopore
Presented at AACR 2026, this recording demonstrates how rapid molecular insights can be leveraged to inform clinical decision-making and advance time-critical cancer care.
